Material
C alcium signaling plays a critical role in T cell activation. TCR ligation is followed by a transient release of calcium from intracellular stores, which precedes a sustained calcium influx through Ca 2+ release-activated Ca 2+ channels that is required for complete activation. Potassium channels play a fundamental role in modulating calcium signaling by providing the counterbalancing cation flux to promote calcium entry through Ca 2+ release-activated Ca 2+ channels (1) (2) (3) . Human T lymphocytes express two types of K + channels, a voltage-gated channel formed by four Kv1.3 subunits and a calcium-activated channel composed of four KCa3.1 subunits (1) . Quiescent human CD4 + and CD8 + T cells express ∼250 Kv1.3 channels and 10-20 KCa3.1 channels per T cell. Human naive and central memory T (T CM ) cells upregulate KCa3.1 upon activation and are inhibited by KCa3.1-specific blockers, whereas effector memory T (T EM ) cells upregulate Kv1.3 and are inhibited by Kv1.3-specific blockers (1, 4, 5) . Thus, the sensitivity of lymphocyte subsets to selective blockers of Kv1.3 and KCa3.1 depends on which channel is predominantly expressed. Genetic suppression of Kv1.3 channels results in reversal of T EM to T CM cells through SMAD3/ p21c1p1 signaling (6, 7) . Kv1.3 clearly has an important functional role in human T EM cells.
During the course of immune, or autoimmune, stimulation, T cells receive a series of activation signals, leading to the conversion into T CM and/or T EM cells. Whereas T CM are important for the maintenance of beneficial immunity, pathogenic T cells in tissue sites of inflammation are typically T EM . Pathogenic T cells in patients with multiple sclerosis (MS), new-onset type 1 diabetes mellitus, rheumatoid arthritis, psoriasis, and acute coronary syndrome are activated T EM cells that express .1000 Kv1.3 channels/ cell (4, (8) (9) (10) (11) . Importantly, pharmacological blockade of Kv1.3 channels has been shown to result in specific inhibition of clonally expanded T EM cell-mediated autoimmune responses while leaving naive and T CM immunity unchanged (4, 8, (12) (13) (14) (15) . Furthermore, Kv1.3 blockers are effective in rodent models of MS (12) (13) (14) (15) , rheumatoid arthritis (8, 16) , contact dermatitis (16) , type 1 diabetes mellitus (8) , autoimmune glomerulonephritis (17) , and psoriasis (10) . Therefore, determining the mechanism by which this ion channel mediates its effects will not only provide insight into the novel role of ion channels in T cell lineage fate determination, but also help to elucidate the mode of action of pharmacologic blockers that may be clinically relevant. Although several selective Kv1.3 channel blockers exist, absolute specificity of a pharmacological agent is difficult to obtain, and maintaining efficient blockade for sustained periods of time while avoiding toxic concentrations of drugs is challenging. We therefore sought to use gene-specific Kv1.3 deletion in mice to assess its role on the differentiation and resulting phenotype of T cells during an inflammatory immune response.
Murine T cells have a very different ion channel expression pattern, both in number and type of channel expressed (1, (18) (19) (20) (21) . Quiescent mouse CD4 + T cells express 10-20 voltage-gated K V channels/cell, which include Kv1.1, Kv1.2, Kv1.3, and Kv1.6 channels, whereas resting mouse CD8 + T cells express 10-20 Kv3.1 channels/cell (18) (19) (20) (21) . Activation of these subsets results in a 6-10-fold increase in the amplitude of the K V current, which appears to be exclusively Kv1.3 channels (1, 20, 21 ). An original study describing the generation of the Kv1.3 knockout (KO) mouse indicated no significant role for Kv1.3 in the development of the immune system (22) . Kv1.3 KO CD4 + CD8 + thymocytes expressed mRNAs and/or proteins for several other K + channels, including Kv1.l, Kv1.4, Kv1.6, Kv2.1, Kv3.1, and KCa2.2, and they also exhibited a compensatory upregulation of anion currents with properties resembling ClC-3 (22) . The immune cells of these mice developed normally with similar numbers of T lymphocytes in the spleen and thymus (22) . There was no evidence of a global impact on T cells, as no significant difference was noted in the proliferation of splenocytes from Kv1.3 KO mice in response to challenge with Con A or anti-CD3 (22) .
As the generation of naive T cells appears to proceed normally, we wanted to determine the role of Kv1.3 in the development of a chronic autoimmune response. Therefore, we compared the susceptibility of Kv1.3-deficient and wild-type (WT) mice to the induction of experimental autoimmune encephalomyelitis (EAE) and further characterized the phenotype of T cells following activation in an inflammatory setting in the absence of this important potassium channel. Our data demonstrate that Kv1.3 plays an important role in Ag-specific activation of CD4 + T cells during the course of EAE and show that this is due, at least in part, to intrinsic defects in the T cells themselves. Moreover, we provide the first evidence, to our knowledge, that deletion of Kv1.3 can affect the differentiation of CD4 + T cells, resulting in the development of CD4 + T cells with regulatory properties. These results indicate that specific and effective blockade of Kv1.3 could be beneficial for the treatment of inflammatory immune-mediated diseases such as MS.
Materials and Methods

Mice
Female C57BL/6, 2D2 TCR-transgenic, and CD45.1 congenic mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and maintained in a federally approved animal facility at The Johns Hopkins University (Baltimore, MD) in accordance with the Institutional Animal Care and Use Committee. Kv1.3 KO mice on the C57BL/6 background were a kind gift from Dr. Leonard Kaczmarek (Yale University, New Haven, CT) and were bred and maintained in our animal facility. All mice were between 7 and 10 wk of age when experiments were performed. Age-and sex-matched C57BL/6 mice or littermates were used in all experiments as controls.
EAE induction
EAE was induced in WT and Kv1.3 KO mice by s.c. injection over two sites in the flank with 100 mg myelin oligodendrocyte glycoprotein (MOG 35-55) peptide (The Johns Hopkins Peptide Synthesis Core Facility) emulsified in CFA (Difco, Detroit, MI). A total of 250 ng pertussis toxin (List Biologicals, Campbell, CA) was administered at the time of immunization and 48 h later by i.p. injection. Mice were monitored daily for clinical signs of EAE and given a clinical score based on the following criteria: 0, no disease; 1, limp tail; 2, hind limb weakness; 3, hind limb paralysis; 4, moribund; and 5, death due to EAE. To measure T cell expansion in vivo, CD45.2 CD4 + T cells from Kv1.3 KO and WT mice were isolated and injected i.v. into WT CD45.1 recipients. The recipients were then immunized to induce EAE as described above.
CD4 + T cell isolation
Spleens and lymph nodes were isolated from Kv1.3 KO or WT mice, and single-cell suspensions were made by passing through a 70-mm nylon cell strainer (BD Biosciences, San Jose, CA 
Tritiated thymidine incorporation proliferation assay
Draining lymph nodes from Kv1.3 KO or WT mice were harvested 7 d postimmunization, and single-cell suspensions were made by passing through a 70-mm cell strainer (BD Biosciences). CD4 + T cells were isolated as described above, and 1 3 10 5 cells/well were plated in a 96-well flat-bottom plate. T cells were restimulated with increasing concentrations of MOG 35-55 and 3 3 10 5 irradiated APCs/well. To assess Agpresentation capabilities of Kv1.3 KO DCs or DCs from Kv1.3 KO or WT mice were generated from the bone marrow of mice using standard protocol of culturing with GM-CSF, as described above. These DCs were then pulsed with 5 mg/ml MOG 35-55 peptide. MOG-pulsed DCs were cultured with CD4 + T cells from 2D2 mice in increasing ratios. Cultures were maintained for 96 h at 37˚C in humidified 5% CO 2 
CFSE proliferation assay
Following isolation, Kv1.3 KO or WT CD4 + T cells were labeled with CFSE (Molecular Probes, Carlsbad, CA) according to the manufacturer's instructions. Briefly, cells were resuspended at a concentration of 1 3 10 6 / ml in 0.1% BSA in PBS and incubated with 0.25 mM CFSE at 37˚C for 10 min. The staining was quenched with addition of five volumes of culture media containing 10% FBS. The cells were centrifuged, washed, and resuspended in complete RPMI 1640 media. The cells were then plated at 1 3 10 6 /ml and stimulated with 5 ml Dynal anti-CD3/CD28 beads (Invitrogen). The cells were cultured for 72 h, stained with an anti-CD4-APC Ab (BD Biosciences), and run on the FACSCalibur flow cytometer (BD Biosciences) to assess cell division. The data were analyzed using FlowJo software (Tree Star, Ashland, OR).
Cell-cycle analysis
A BrdU flow kit (BD Pharmingen, San Diego, CA) was used to determine the cell-cycle kinetics. The assay was performed according to the manufacturer's protocol. Briefly, cells were stimulated with anti-CD3/CD28 beads (1 3 10 6 /well), and 10 mM BrdU was added for the final 18 h of culture. Cells were fixed in a solution containing paraformaldehyde and the detergent saponin and incubated for 1 h with DNAase at 37˚C (30 mg/ sample). APC-conjugated anti-BrdU Ab (1:50 dilution in Wash buffer; BD Pharmingen) was added and incubation continued for 20 min at room temperature. Cells were washed in Wash buffer, and total DNA was stained with 7-aminoactinomycin D (7-AAD; 20 ml/sample). BrdU content and total DNA content (7-AAD) were analyzed on an FACSCalibur flow cytometer (BD Biosciences) using CellQuest software (BD Immunocytometry Systems, San Jose, CA). (4, 23, 24) . Cell capacitance, a direct measure of cell surface area, was constantly monitored during recording. Statistical differences in channel number per cell were determined by Student t test.
Electrophysiology
Perfusion and immunostaining
Kv1.3 KO or WT EAE mice were anesthetized, perfused with HBSS, and spleens and brains were removed. CNS tissue was digested and enriched for mononuclear cells. Single-cell suspensions were made from spleens as described above. Collected cells were stimulated in media containing PMA (50 ng/ml; Sigma-Aldrich), ionomycin (1 mg/ml; Sigma-Aldrich), and monensin (4 ml/6 ml; GolgiStop; BD Biosciences) at 37˚C for 4-6 h. Cells were washed with FACS buffer (2% FBS in PBS) and surface stained with anti-CD3 PerCP or APC, anti-CD4 PerCP or APC, anti-CD44 FITC, anti-CD62L PE, anti-CD25 FITC, anti-CD45.2 FITC, Va3.2 FITC, Vb11 PE, and Annexin V (BD Biosciences and eBioscience, San Diego, CA). Cells were then fixed and permeabilized using the Foxp3 staining kit (eBioscience) and stained for intracellular cytokines with anti-IFN-g FITC, anti-IL-17 APC, anti-Foxp3 APC, and anti-IL-10 PE (BD Biosciences). Flow cytometry was performed using an FACSCalibur flow cytometer (BD Biosciences), and data were analyzed using FlowJo software (Tree Star, Ashland, OR).
ELISA
CD4
+ T cells were isolated from unimmunized Kv1.3 KO or WT mice as described above and stimulated for 72 h or 4 d followed by a 3-d rest period with Dynal anti-CD3/CD28-coated beads (Invitrogen) for a total of three cycles. Supernatants were collected 72 h following the first and third stimulation, and cytokine secretion was measured by ELISAs. DCs generated from bone marrow of WT or Kv1.3 KO mice were stimulated with or without 5 ng/ml LPS overnight, and IL-6 production was measured by ELISA. IFN-g, IL-17, IL-10, and IL-6 ELISAs were performed using mouse ELISA kits specific for the aforementioned cytokines according to the manufacturer's protocols (BioLegend, San Diego, CA, and R&D Systems, Minneapolis, MN).
Western blotting
CD4
+ T cells were isolated from unimmunized Kv1.3 KO or WT mice and stimulated with anti-CD3/CD28-coated beads for 4 d followed by a 3-d rest period. Cells were restimulated and rested in the same manner for a total of three cycles, followed by a final 6-h stimulation. Cells were collected and lysed with RIPA buffer (Boston Bioproducts, Ashland, MA) to generate whole-cell lysate. Protein was quantitated using the BCA assay (Pierce, Rockford, IL). Lysates were electrophoretically separated using 12% Tris HCl gels (Bio-Rad, Hercules, CA) and transferred to nitrocellulose membranes. Western blotting was performed using the following Abs: p-Smad3, Smad3, Actin, and goat anti-rabbit IgG-HRP (Cell Signaling Technologies, Danvers, MA). Average densitometric ratio was calculated for each blot by normalizing to an actin loading control using ImageJ software (National Institutes of Health).
In vitro suppression assay
CD4
+ T cells from unimmunized Kv1.3 KO or WT mice were stimulated with anti-CD3/CD28 beads for three rounds as described above. Immediately preceding the third stimulation, Kv1.3 KO or WT T cells were incubated with WT naive CD4 + CFSE-labeled responder cells at a ratio of suppressors/responders of 5:1. The cells were stimulated with anti-CD3/ CD28 beads for an additional 72 h, and proliferation of responder cells was assessed using an FACSCalibur flow cytometer (BD Biosciences). Data were analyzed using FlowJo software (Tree Star). For ex vivo suppression assays, CD4 + T cells were isolated from MOG 35-55-immunized Kv1.3 KO or WT mice 22 d postimmunization and incubated with WT naive CD4 + CFSE-labeled responder cells at a ratio of suppressors/responders of 5:1. The cells were stimulated with anti-CD3/CD28-coated beads for an additional 72 h and proliferation of responder cells was assessed using an FACSCalibur (BD Biosciences) flow cytometer. Data were analyzed using FlowJo software (Tree Star).
Statistics
Statistical evaluation of significance between the experimental groups was determined by Student unpaired t test, Mann-Whitney U nonparametric analysis, or ANOVA as appropriate using GraphPad Prism (GraphPad, San Diego, CA). Results were determined to be statistically significant when p , 0.05: *p , 0.05, **p , 0.01, ***p , 0.001.
Results
Kv1.3 KO mice have a decreased incidence and severity of EAE and a limited proliferative capacity of lymphocytes
To investigate the effect of specific inhibition of Kv1.3 on CD4 + T cell differentiation during an immune-mediated disease, we induced EAE in Kv1.3 KO and WT C57BL/6 mice by immunization with MOG 35-55 peptide. Interestingly, WT mice developed severe EAE accompanied by loss of weight, whereas Kv1.3 KO mice had significantly decreased incidence and severity of EAE and no loss of weight over the course of the experiment (Fig.  1A, 1B) . Moreover, Kv1.3 KO mice that did develop signs of EAE had a delayed onset of disease and recovered more completely and at a faster rate than WT controls (data not shown).
To determine whether protection from EAE was mediated by the inability of Kv1. Fig. 1A, 1B) . Unimmunized animals were also found to have similar numbers of naive, T CM , and T EM cells in the spleen and lymph node as determined by expression of CD62L and CD44 (Supplemental Fig. 1C ). In contrast, MOG-immunized Kv1.3 KO mice had significantly more naive and T CM cells and fewer T EM cells in the lymph node at 7 d postimmunization than WT controls (Fig. 1C, 1D ). In addition, Kv1.3 KO mice had significantly fewer activated CD4 + T cells, as characterized by change in expression of CD25 in Foxp3 2 cells (gating strategy shown in Supplemental Fig. 2 ) in the lymph node 7 d following immunization (Fig. 1E ). These observations were further validated by the relative lack of proliferation of CD4 + T cells from Kv1.3 KO mice following rechallenge with the immunizing Ag ex vivo, as compared with WT cells (Fig. 1F) . These findings suggest that CD4 + T cells from Kv1.3 KO mice do not become fully activated following antigenic challenge in vivo and, as a result, retain a naive phenotype and have a limited proliferative capacity. The Journal of Immunology(Supplemental Fig. 1D ). However, in mice immunized to induce EAE, there was a significant decrease in the production of proinflammatory IFN-g and IL-17 cytokines from CD4 + T cells in the spleens of Kv1.3 KO mice compared with WT controls (Fig.  2A, 2B ). This decrease in IFN-g and IL-17 correlated with the decreased incidence and severity of disease in the KO mice.
Because we wanted to determine whether the protection from EAE was associated with a defect in activation and recruitment of encephalitogenic cells to the CNS, we investigated whether the loss of Kv1.3 drove a change in cytokine secretion from CD4 + T cells in the brains of immunized mice. We found a significant decrease in the percentage of CD4 + T cells (WT: 4.7 6 0.8%; KO: 2.2 6 0.5%) in the brains of Kv1.3 KO mice compared with WT mice; further, of the cells that were present, significantly fewer were producing IFN-g and IL-17 (Fig. 2C, 2D ). These data suggest that CD4 + T cells from Kv1.3 KO mice are impaired in their ability to become fully activated in response to antigenic stimulation and, therefore, do not readily migrate to the CNS. 
cell blasts
We used whole-cell patch-clamp to characterize the K V channel expression in disease-associated MOG-35-55-stimulated CD4 + T cell blasts from the spleens of WT mice with EAE. Eight days following immunization with MOG 35-55, mice with EAE were euthanized, CD4 + T cells were isolated from the spleen, restimulated ex vivo with MOG 35-55 peptide for 48 h, and frozen, and patch-clamp studies were performed. Robust K + currents (Fig. 3A ) with properties closely resembling Kv1.3 were detected (cell capacitance .4 pF, 11-mm diameter). They exhibited cumulative inactivation, a unique property of Kv1.3 that distinguishes it from other voltage-gated K + channels (Fig. 3C) . The half-maximal ac- tivation voltage of the current was similar to that of cloned Kv1.3 ( Fig. 3B) (24) . The specific Kv1.3 inhibitor ShK-186 (4) completely inhibited the T cell current (Fig. 3D) . The CD4 + MOGrestimulated WT blasts expressed 336 6 23 Kv1.3 channels/cell (Fig. 3F) . These results indicate that Kv1.3 is the only voltagegated K + current in MOG-activated WT CD4 + T cell blasts and confirms earlier work (20, 21) . Calcium-activated KCa3.1 channels were not detected in these experiments because the pipette solution contained EGTA and no calcium.
Immunization of Kv1.3 KO mice with MOG 35-55 resulted in a significantly decreased incidence and severity of EAE (Fig. 1A) . Nevertheless, some CD4 + splenic T cells isolated from these mice 8 d postimmunization and restimulated ex vivo with MOG 35-55 did undergo activation based on cell size (.4 pF cell capacitance, 11-mm diameter). However, no outward K + current was detectable in the Kv1.3 KO CD4 + MOG 35-55-stimulated T cell blasts (Fig.  3E, 3F ). These results demonstrate that MOG 35-55-restimulated Kv1.3 KO CD4 + T blasts lack K V current, and more importantly, the absence of Kv1.3 may contribute to the inability of these mice to mount a MOG-specific EAE response.
CD4
+ T cells from Kv1.3 KO mice have an intrinsic defect in activation that is not associated with increased cell death
We reported previously that genetic silencing of Kv1.3 in human CD4
+ T EM cells with a dominant-negative Kv1 construct results in cell-cycle delay at the G 2 /M phase, and this delay is likely responsible for the decreased activation and proliferation of these cells (7) . To determine whether such a delay contributed to the decreased proliferative capacity of Kv1.3 KO CD4 + T cells, we analyzed the ability of Kv1.3 KO CD4 + T cells to progress through the cell cycle using a flow cytometric BrdU incorporation assay. CD4 + T cells isolated from spleens of 10-wk-old WT or Kv1.3 KO mice were stimulated with anti-CD3/CD28 beads and pulsed with 10 mM of BrdU for the final 18 h of stimulation. The proportion of BrDU + CD4 + T cells was significantly lower in Kv1.3 KO mice compared with WT mice (Fig. 4A) . Cell-cycle progression was analyzed by measuring incorporated BrdU and total DNA levels (7-AAD) by flow cytometry (Fig. 4B, 4C ). Roughly 18% of activated WT CD4 + T cells were in the G 2 /M phase, and 24% reached the S phase of the cell cycle (Fig. 4B,  4C ). In Kv1.3 KO CD4 + T cells, significantly more cells remained in the G 2 /M phase (∼25%), and fewer cells reached the S phase (11%) (Fig. 4B, 4C ), indicating that cell-cycle delay contributes to the diminished proliferative capacity of Kv1.3 KO CD4 + T cells. CFSE proliferation assays confirmed this finding. CD4 + T cells isolated from Kv1.3 KO mice and stimulated with anti-CD3/CD28 proliferated more slowly than CD4 + T cells from WT mice (Fig.  4D) . No increase in apoptosis of Kv1.3 KO CD4 + T cells was noted in comparison with controls (Fig. 4E) (Fig. 5A ). These data suggest that an intrinsic defect in CD4 + T cells rather than a defect in APCs is responsible for the inability of Kv1.3 KO mice to mount an effective MOG 35-55-specific immune response and develop EAE.
To investigate directly the effect of Kv1.3 deletion on the ability of DCs to present Ag and activate T cells, we performed an in vitro proliferation assay using DCs generated from the bone marrow of WT or Kv1.3 KO mice. WT or Kv1.3 KO DCs were pulsed with 5 mg/ml of MOG 35-55 peptide, plated with 2D2 TCR-transgenic CD4 + T cells, and the proliferation of the T cells was measured using tritiated thymidine incorporation. DCs generated from Kv1.3 KO bone marrow induced T cell proliferation to the same extent as WT DCs (Fig. 5B) , suggesting that deletion of Kv1.3 in DCs does not impair their ability to present Ag and activate T cells. IL-6 production by DCs during the course of EAE is believed to be important for disease pathogenesis (27) . To determine whether decreased production of IL-6 contributed to the decreased incidence and severity of EAE that we observed in our Kv1.3 KO mice, DCs generated from Kv1.3 KO or WT mice were stimulated with LPS overnight, and IL-6 production was measured by ELISA. There was no difference in LPS-induced IL-6 production from WT and Kv1.3 KO mice (Fig. 5C ), suggesting that deficiency in IL-6 production from DCs does not contribute to the decreased severity of EAE in the Kv1.3 KO animals.
+ T cells from Kv1.3 KO mice secrete more IL-10 in vitro and ex vivo following induction of EAE Because CD4 + T cells from Kv1.3 KO mice were characterized by a delayed or decreased proliferative capacity, we examined whether they exhibited properties common to regulatory T cells (T regs ). T regs proliferate more slowly than other types of effector T cells and produce more IL-10 and less IL-17 and IFN-g, which contributes to their ability to suppress autoreactive effector T cells (28) . Moreover, anergic T cells have been shown to act as suppressor cells in vitro (29, 30 + T cells were isolated from spleens of 10-wk-old unimmunized Kv1.3 KO and WT mice. Cells were labeled with CFSE and stimulated with anti-CD3/CD28 beads for 72 h. Flow cytometry was performed to assess the amount of cell division as measured by CFSE dilution compared with unstimulated cells. CD4 + T cells from Kv1.3 KO mice divided more slowly than cells from WT mice with 57 versus 78% division, respectively. (E) CD4 + T cells were isolated from Kv1.3 KO and WT mice and stimulated as described in (A). Cells were stained for CD4 and Annexin V to measure cell death. There was no difference detected in the number of apoptotic CD4 + T cells between Kv1.3 KO and WT mice. All data are representative of three independent experiments. Statistical significance was determined with *p , 0.05. staining for IL-10. CD4 + T cells from spleens of unimmunized Kv1.3 KO and WT mice did not produce significant amounts of IL-10 and had an equal number of Foxp3 + cells (Supplemental Fig. 1E ). In contrast, CD4 + T cells from Kv1.3 KO mice immunized to induce EAE made significantly more IL-10 than WT controls, consistent with a regulatory phenotype (Fig. 6A, 6B) . Interestingly, this increase in IL-10 production was not associated with an increase in the percentage of Foxp3 + cells, suggesting that this population of cells differs from canonical induced T regs .
We confirmed enhanced IL-10 secretion by CD4 + T cells from Kv1.3 KO mice independent of effects from APCs. CD4 + T cells from unimmunized Kv1.3 KO or WT mice were subjected to one to three rounds of in vitro stimulation with anti-CD3/CD28 beads, in which each round consisted of activation for 3 to 4 d followed by a rest period of 3 d. The multiple rounds of stimulation were performed to generate T cells with an effector memory phenotype, as effector memory cells have been demonstrated to be more dependent on Kv1.3 signaling. Supernatants were collected 72 h after the first or third round of stimulation, and IL-10, IFN-g, and IL-17 production was measured by ELISA. CD4 + T cells from Kv1.3 KO mice made significantly more IL-10 than cells from WT mice with a correlating decrease in IFN-g and IL-17 production after one (Fig. 6C) or three (Fig. 6D ) rounds of stimulation in vitro. These data suggest that CD4 + T cells from Kv1.3 KO mice have impaired effector functions and intrinsic regulatory properties.
CD4 + T cells from Kv1.3 KO mice acquire regulatory properties and suppress activation of naive T cells in vitro and ex vivo
To further evaluate the regulatory capabilities of Kv1.3 KO T cells, we performed functional assays in vitro and directly ex vivo following induction of EAE. We previously reported that genetic silencing of Kv1.3 by a dominant-negative Kv1.X lentivirus induces an increase in expression of phosphorylated SMAD3 in human CD4 + T cells (7) . Phosphorylation of SMAD3 occurs in response to TGF-b signaling and has been shown to be important for the development of T regs (31) (32) (33) . Furthermore, phosphorylation of SMAD3 and its association with SMAD4 has been proposed to induce transcription of IL-10 in murine CD4 + T cells (34) . We therefore examined whether enhanced IL-10 production by Kv1.3 KO CD4 + T cells was a result of increased SMAD3 phosphorylation. Phosphorylation of SMAD3 was measured by Western blotting in CD4 + T cells from WT and Kv1.3 KO mice that had undergone three rounds of in vitro stimulation with anti-CD3/CD28 beads. CD4 + T cells from Kv1.3 KO mice had increased expression of phosphorylated SMAD3 compared with WT T cells (Fig. 7A, 7B ). This finding supports the possibility that deletion of Kv1.3 skews the differentiation of CD4 + T cells toward a regulatory phenotype.
A functional characteristic that is a hallmark of a regulatory cell is its capability to suppress effector T cells. We performed a functional suppression assay to determine whether Kv1.3 KO CD4 + T cells exhibit suppressor activity. CD4 + T cells from WT and Kv1.3 KO mice were subjected to three rounds of stimulation. These suppressor cells were then incubated with CFSE-labeled WT CD4
+ responder cells at a ratio of 5:1. The mixture of cells was stimulated with anti-CD3/CD28 beads for 72 h, and proliferation of responder cells measured using flow cytometry. CD4 + T cells from Kv1.3 KO mice suppressed the activation of WT CD4 + T cells, with ∼23% of cells remaining undivided compared with 5% in controls (Fig. 7C) . Unstimulated CD4 + T cells isolated from unimmunized Kv1.3 KO mice did not suppress the activation of WT CD4 + T cell responders, suggesting that the suppressive properties of Kv1.3 KO T cells are acquired only after stimulation (Supplemental Fig. 1F) .
To confirm the ability of Kv1.3 KO CD4 + T cells to suppress effector cells in vivo, CD4 + T cells were isolated from Kv1.3 KO or WT mice 22 d postimmunization with MOG 35-55. These cells were plated with CFSE-labeled WT CD4 + T cells in the presence of anti-CD3/CD28 beads, and the proliferation of responder cells was measured after 72 h using flow cytometry. As seen in vitro, CD4 + T cells from Kv1.3 KO MOG-immunized mice suppressed effector CD4 + T cells, with ∼50% of cells remaining undivided compared with 14% in controls (Fig. 7D) . Interestingly, this suppressive phenotype did not correlate with an increase in the percentage of Foxp3 + cells, consistent with the idea that these suppressor cells differ from canonical T regs (Fig. 7E) . These data further support the hypothesis that CD4 + T cells from Kv1.3 KO mice have the propensity to acquire a regulatory phenotype, which could account for the limited proliferative capacity of T cells and the lower incidence and severity of EAE in Kv1.3 KO animals.
Discussion
Controlled regulation of T cell activation in the context of inflammation has been the topic of numerous investigations through the years. The data presented in this study provide evidence that effective targeting of the Kv channel Kv1.3 on CD4 + T cells could result in the development of T cells with decreased proliferative capacity and a regulatory phenotype that would be beneficial for controlling unwanted immune responses.
We used Kv1.3 KO mice to determine the specific contribution of the Kv1.3 channel to T cell activation and differentiation during the course of MOG-induced EAE. We found that Kv1.3 KO mice were resistant to the development of EAE with significantly decreased incidence and severity of disease compared with WT controls. Upon further examination, we found that CD4 + T cells isolated from lymph nodes of immunized mice were refractory to restimulation with MOG 35-55 peptide in vitro and maintained more of a naive phenotype than WT counterparts. The resistance of Kv1.3 KO mice to EAE was also associated with decreased production of IFN-g and IL-17 by CD4 + T cells and fewer encephalitogenic T cells in the brains of affected animals. Quiescent mouse T cells express fewer K V channels than human T cells (20 versus 250/cell) and multiple K V family members-Kv1.1, Kv1.2, Kv1.3, Kv1.6, and Kv3.1-in contrast to human T cells that only express Kv1.3 (1) . Because of these differences, it is widely believed that mouse T cells are less sensitive to blockade or absence of Kv1.3 (1, 35, 36) . In addition, it has been suggested that murine T cells differ from human T cells in maintaining high levels of KCa3.1 upon acquiring an effector memory phenotype, again making them less sensitive to Kv1.3 blockade (1, 35) . Our results demonstrate that Kv1.3 is the only Kv channel in murine MOG 35-55-restimulated CD4 + T blasts, and these cells from Kv1.3 KO mice exhibit a complete absence of Kv current. Moreover, the absence of Kv current prevents the mice from mounting an MOGspecific EAE response. The likely presence of other channels in these cells, chloride channels previously described in thymocytes from Kv1.3 KO mice (22) and calcium-activated KCa3.1 channels (35, 37) , does not appear to be sufficient to induce EAE. Perhaps Kv1.3 channels play important hitherto undefined roles by virtue of their participation in signaling complexes in T cells (1), besides their well-accepted role in the regulation of membrane potential and calcium signaling. Moreover, the availability of these mice has allowed us to gain insight into how blockade of Kv1.3 could affect the ability of CD4 + T cells to differentiate into pathogenic Th1 or Th17 cells. In addition, our data do not contradict initial findings in the Kv1.3 KO mouse, but rather extend those findings to suggest that although the development of the mouse is grossly normal, an immunological phenotype is present in effector T cells when the mouse is challenged in an Ag-specific manner.
Because Kv1.3 is known to be expressed on a variety of cell types, including APCs (25, 26) + T cells and a consequence of MOG immunization. These data suggest that whereas the ability of Kv1.3-deficient APCs to present Ag to T cells in vivo may be impaired, there is an intrinsic defect in the T cells themselves, which is preventing them from responding to a properly presented Ag. These data were confirmed using in vitro assays in which CD4 + T cells were isolated and their ability to progress through the cell cycle and proliferate in response to anti-CD3/CD28 bead stimulation was measured using BrdU incorporation and a CFSE assay. We have published recently that human T EM CD4 + T cells transduced with a dominant-negative Kv1.3 construct display a delay in transition from the G 2 /M to the S phase of the cell cycle. This change correlated with an increase in phosphorylation of SMAD3 and p21 expression and likely contributes to the decreased proliferative capacity of the KvDNtransduced cells (7) . Similarly, we found an increase in Kv1.3 KO CD4 + T cells in G 2 /M phase and a decrease in S phase compared with WT controls. These data suggest that cell cycle delay might contribute to the decreased proliferative capacity of CD4 + T cells from Kv1.3 KO mice. Moreover, a CFSE assay showed that proliferation of Kv1.3 KO CD4 + T cells was delayed but not completely impaired compared with WT controls fol- + T cells are unable to progress through the cell cycle and become fully activated because of a defect in cell signaling or because the cells differentiate into a subset with a lower proliferative capacity.
T regs exhibit a lower proliferative capacity and produce more IL-10 and less IL-17 and IFN-g than other types of effector T cells (28) (39, 40) . We published recently that dominant-negative suppression of Kv1.3 expression in human CD4 + T EM cells leads to phosphorylated SMAD3-mediated cell-cycle delay (7) . Interestingly, phosphorylated SMAD3 accumulates in the nuclei of IL-10-secreting Kv1.3 KO CD4 + T cells with suppressor activity. TGF-b-induced SMAD 2/3 phosphorylation is followed by nuclear translocation and association with SMAD4, which induces transcription of IL-10 (34). Therefore, depletion of intracellular calcium and the resulting inhibition of the calcium-calmodulin II kinase, as may occur in the absence of Kv1.3, may activate the SMAD complex (41, 42) and lead directly to increased IL-10 production and the nonclassical T reg subset that develops in MOG-immunized Kv1.3 KO mice.
Taken together, these data suggest that in the absence of Kv1.3, antigenic stimulation induces differentiation of CD4 + T cells into a unique population of Ag-specific T regs rather than into effector cells. Immunoregulatory CD4 + CD25 + T cells that secrete IL-10 have been demonstrated to play an important role in peripheral tolerance to self-Ags in mice and humans (43) . Naturally occurring T regs have a low proliferative capacity and inhibit proliferation of CD4 + CD25 2 T cells (44) . CD4 + T cells from Kv1.3 KO mice display both of the aforementioned characteristics, suggesting that animals deficient in Kv1.3 may acquire more natural T regs during development. T regs have been explored for therapeutic purposes for a number of inflammatory diseases (45-47), and our data suggest that pharmacological blockade or genetic suppression of Kv1.3 could provide a novel approach to generate Ag-specific T regs with the capacity to suppress unwanted immune responses.
The data presented in this study demonstrate the importance of the K + channel Kv1.3 for the activation of CD4 + T lymphocytes in an Ag-specific mouse model of inflammation/autoimmunity. CD4 + T cells from Kv1.3-deficient mice exhibit a decreased overall proliferative capacity that is, at least in part, due to an intrinsic defect in the T cells themselves. This decreased proliferative capacity is associated with the development of T cells with regulatory properties and results in a significantly decreased susceptibility to EAE. Further investigation into the downstream pathways that are directly affected by Kv1.3 deficiency and the molecular mechanism by which these pathways are altered could provide new insight into the development of novel therapies focused on the enhancement of T regs . Overall, these data suggest that specific and potent blockade of Kv1.3 could be beneficial for the treatment of immune-mediated inflammatory diseases such as MS.
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